Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics, PerkinElmer Ink Deal to Broaden Access to Genetic Carrier Screening Tests

NEW YORK (GenomeWeb News) – Good Start Genetics today announced a deal with PerkinElmer to expand access to the GoodStart Select menu of genetic carrier screening tests.

Under the terms of the agreement, PerkinElmer will be Good Start's exclusive commercial sales and marketing partner in the US and offer the GoodStart Select tests to targeted physicians who are not in Good Start's current network of clinicians in the in vitro fertilization space. The deal expands the market for the GoodStart Select tests to the broader women's health community, including obstetrics and gynecology, as well as maternal fetal medicine doctors, Good Start said.

Based in Cambridge, Mass., the company develops tests that provide molecular genetic information. GoodStart Select is a portfolio of genetic carrier screening tests based on technologies that include next-generation sequencing. According to Good Start, the tests provide higher mutation detection rates and fewer missed carriers than traditional screening technologies.

"Collaborating with PerkinElmer will allow us to reach more of the 60 million reproductive age women who are candidates for genetic carrier screening, and ultimately help more couples better assess their risks of, and options to avoid, having a baby with a debilitating or fatal inherited genetic disorder," Good Start Genetics President and CEO Don Hardison said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.